Cell Therapy

R&D

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome

News

Gilead buys in vivo cell therapy firm Interius for $350m

Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.

Partner Content

7th Cell Therapy Analytical Development Summit

Join us in fast-tracking the next era of safe, potent, and robust cell therapies to market!

News

Galapagos drops plan to split after 'market developments'

Shortly after announcing a plan to separate its drug and cell therapy businesses into two separate companies, Galapagos has had a change of heart.

R&D

For cell therapies, raw material quality hinges on the human...

When it comes to cell-based therapy manufacturing, the concept of quality management carries important distinctions from more traditional therapeutics production.

News